Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Chief Financial Officer | March 24, 2020 | March 26, 2020 |
| Insys Therapeutics, Inc.INSY · Entity 156931 | Director | March 04, 2019 | April 23, 2019 |
| KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686 | Chief Financial Officer | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDOLOGIX INC /DE/
Report date March 24, 2020 · Filed March 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,716 |
Ending reported balance
After 2020-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-24 · Grant · Acquired 47,010 · Balance 115,341 F1: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. 8,865 shares subject to this restricted stock unit award vested based on the achievement of specified Company performance criteria pursuant to the terms of this award. Row 2 · 2020-03-24 · Tax withholding · Disposed 3,625 · Balance 111,716 F2: Shares withheld on March 24, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on March 11, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. 8,865 shares subject to this restricted stock unit award vested based on the achievement of specified Company performance criteria pursuant to the terms of this award.
F2: Shares withheld on March 24, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on March 11, 2020.
Insys Therapeutics, Inc.
Report date March 04, 2019 · Filed April 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,083 |
Reported balance
After 2019-03-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 8,083 · Balance 14,083 F1: The total reported in Column 5 includes 6,000 RSUs previously reported in Table II on 2/21/18. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-03-03 | Direct | 20,935 |
Reported balance
After 2019-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-04 · Grant · Acquired 20,935 · Balance 20,935 F2: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The total reported in Column 5 includes 6,000 RSUs previously reported in Table II on 2/21/18.
F2: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022.
KESTRA MEDICAL TECHNOLOGIES, LTD.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 60,609 |
Ending reported balance
After 2026-08-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Sale · Disposed 25,787 · Balance 61,109 F1: The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025. F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.3100 to $26.3050. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Row 2 · 2026-08-07 · Sale · Disposed 500 · Balance 60,609 F1: The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025. F3: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.3150 to $26.3600. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.
F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.3100 to $26.3050. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F3: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.3150 to $26.3600. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 21:56 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 500 | $26.33 | $13,165.00 |
DisclosureSEC source: 0001193125-26-345169 · ownership.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,609 F1 · kind: The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025. F3 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.3150 to $26.3600. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 21:56 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 25,787 | $25.87 | $667,218.00 |
DisclosureSEC source: 0001193125-26-345169 · ownership.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,109 F1 · kind: The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025. F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.3100 to $26.3050. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 23:04 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 3,915 | $25.17 | $98,538.98 |
DisclosureSEC source: 0001193125-26-338665 · ownership.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,896 F3 · kind: The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025. F4 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0000 to $25.3800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 23:04 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 3,080 | $24.06 | $74,095.56 |
DisclosureSEC source: 0001193125-26-338665 · ownership.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,811 F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9030 to $24.4200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 23:30 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 5,391 | $23.80 | $128,312.27 |
DisclosureSEC source: 0001193125-26-331062 · ownership.xml · nonDerivative · entry 3 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,891 F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F4 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6400 to $23.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 23:30 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 8,817 | $22.61 | $199,344.43 |
DisclosureSEC source: 0001193125-26-331062 · ownership.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,282 F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F3 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1600 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 23:30 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 3,980 | $22.75 | $90,560.52 |
DisclosureSEC source: 0001193125-26-331062 · ownership.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,099 F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.3300 to $23.0300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 21:50 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 44,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308045 · ownership.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,079 F1 · shares: Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 22:37 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 25,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-257911 · ownership.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,961 F1 · shares: Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. ("Common Share"). Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026. F2 · balance_after: Includes 5,837 Common Shares received from West Affum Holdings, L.P. in a pro rata distribution exempt pursuant to Rule 16a-9. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 21:14 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 22,059 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097321 · ownership.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,897 F1 · shares: Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest 7,353 on July 17, 2026, 7,353 on July 17, 2027 and 7,354 on July 17, 2028. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 16:36 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 3,625 | $0.94 | $3,407.50 |
DisclosureSEC source: 0001013606-20-000048 · wf-form4_158525496049212.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,716 F2 · shares: Shares withheld on March 24, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on March 11, 2020. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 16:36 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 47,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-20-000048 · wf-form4_158525496049212.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,341 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. 8,865 shares subject to this restricted stock unit award vested based on the achievement of specified Company performance criteria pursuant to the terms of this award. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 16:15 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 3,393 | $1.68 | $5,700.24 |
DisclosureSEC source: 0001013606-20-000004 · wf-form4_157799971520536.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,341 F2 · shares: Shares withheld on December 30, 2019 to satisfy statutory minimum tax withholding obligations related to shares vested on December 30, 2019. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 16:15 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 47,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-20-000004 · wf-form4_157799971520536.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,734 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. 50% of the 20,147 shares subject to this restricted stock unit award vested pursuant to the terms of this award. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 14:17 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 2,986 | $2.55 | $7,599.37 |
DisclosureSEC source: 0001013606-19-000194 · wf-form4_157661022809711.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,733 F2 · shares: Shares withheld on December 13, 2019 to satisfy statutory minimum tax withholding obligations related to shares vested on December 04, 2019. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 14:17 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 47,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000194 · wf-form4_157661022809711.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,719 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. 33% percent of the 28,863 shares subject to this restricted stock award vested pursuant to the terms of this award. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 10,959 | Not disclosed Strike: $4.71 | Not disclosed |
DisclosureSEC source: 0001013606-19-000170 · wf-form4_156996183385541.xml · derivative · entry 4 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,959 Underlying: Common Stock · 10,959 shares Expires 2026-09-10 F4 · shares: The options vest in three equal annual installments over a three-year period commencing on September 10, 2019. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 13,702 shares of common stock granted to the reporting person on October 15, 2015, (ii) an option for 11,594 shares of common stock granted to the reporting person on February 4, 2016, and (iii) an option for 10,999 shares of common stock granted to the reporting person on May 31, 2017. In exchange, the reporting person received a new stock option, for 10,959 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 10,999 | Not disclosed Strike: $48.20 | Not disclosed |
DisclosureSEC source: 0001013606-19-000170 · wf-form4_156996183385541.xml · derivative · entry 3 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,999 shares Expires 2027-05-31 F3 · shares: Options vested ratably over forty-eight months. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 13,702 shares of common stock granted to the reporting person on October 15, 2015, (ii) an option for 11,594 shares of common stock granted to the reporting person on February 4, 2016, and (iii) an option for 10,999 shares of common stock granted to the reporting person on May 31, 2017. In exchange, the reporting person received a new stock option, for 10,959 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 11,594 | Not disclosed Strike: $75.30 | Not disclosed |
DisclosureSEC source: 0001013606-19-000170 · wf-form4_156996183385541.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,594 shares Expires 2026-02-04 F3 · shares: Options vested ratably over forty-eight months. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 13,702 shares of common stock granted to the reporting person on October 15, 2015, (ii) an option for 11,594 shares of common stock granted to the reporting person on February 4, 2016, and (iii) an option for 10,999 shares of common stock granted to the reporting person on May 31, 2017. In exchange, the reporting person received a new stock option, for 10,959 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 13,702 | $0.00 Strike: $135.60 | $0.00 |
DisclosureSEC source: 0001013606-19-000170 · wf-form4_156996183385541.xml · derivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,702 shares Expires 2025-10-15 F1 · shares: Twenty-five percent of the options vested upon one year of service and the remaining balance continued to vest in equal monthly installments thereafter. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 13,702 shares of common stock granted to the reporting person on October 15, 2015, (ii) an option for 11,594 shares of common stock granted to the reporting person on February 4, 2016, and (iii) an option for 10,999 shares of common stock granted to the reporting person on May 31, 2017. In exchange, the reporting person received a new stock option, for 10,959 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 17:16 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 64,800 | $6.67 Strike: $6.67 | $432,216.00 |
DisclosureSEC source: 0001013606-19-000134 · wf-form4_156512616822805.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 Underlying: Common Stock · 64,800 shares Expires 2029-08-05 F2 · shares: Options vest ratably over thirty-six months. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 17:16 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 32,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000134 · wf-form4_156512616822805.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,720 F1 · shares: Performance restricted stock unit award based on predetermined goals. Read SEC document |
| April 03, 2019 Filed Apr 3, 2019 16:16 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000076 · wf-form4_155432257105252.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,320 F1 · shares: 100% of the time-based restricted stock unit award shall vest on October 3, 2019 and shall settle in shares of common stock. Read SEC document |
| April 03, 2019 Filed Apr 3, 2019 16:16 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Stock | 15,128 | $6.61 | $99,996.08 |
DisclosureSEC source: 0001013606-19-000076 · wf-form4_155432257105252.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,820 Read SEC document |
| March 04, 2019 Filed Apr 19, 2019 21:35 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 20,935 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001209191-19-025412 · doc4.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,935 Underlying: Common Stock · 20,935 shares Expires 2029-03-03 F2 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022. Read SEC document |
| March 04, 2019 Filed Apr 19, 2019 21:35 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025412 · doc4.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 F1 · balance_after: The total reported in Column 5 includes 6,000 RSUs previously reported in Table II on 2/21/18. Read SEC document |
| March 04, 2019 Filed Apr 23, 2019 19:15 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 20,935 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001209191-19-025633 · doc4.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,935 Underlying: Common Stock · 20,935 shares Expires 2029-03-03 F2 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on March 4, 2022. Read SEC document |
| March 04, 2019 Filed Apr 23, 2019 19:15 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025633 · doc4.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 F1 · balance_after: The total reported in Column 5 includes 6,000 RSUs previously reported in Table II on 2/21/18. Read SEC document |
| December 30, 2018 Filed Jan 2, 2019 21:01 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 225,621 | $0.74 Strike: $0.74 | $167,974.83 |
DisclosureSEC source: 0001013606-19-000021 · wf-form4_154648087116506.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,621 Underlying: Common Stock · 225,621 shares Expires 2028-12-30 F2 · shares: 100% of the option award shall vest on December 30, 2019. Read SEC document |
| December 30, 2018 Filed Jan 2, 2019 21:01 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 470,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000021 · wf-form4_154648087116506.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,927 F1 · shares: (i) 201,478 time-based restricted stock units (RSUs) vest in two equal annual installments on December 30, 2019 and December 30, 2020, and (ii) 268,637 RSUs vest as to 100% of the underlying shares on December 30, 2021, provided that the vesting of the RSUs shall be subject to acceleration based on the achievement of specified Company and/or individual performance criteria to be approved by the Company's compensation committee. All RSUs granted shall settle in shares of common stock on each of the dates indicated. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 16:19 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Shares | 30,000 | $2.43 | $72,900.00 |
DisclosureSEC source: 0001013606-18-000126 · wf-form4_153479636718221.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,812 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 16:26 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerCommon Shares | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-18-000029 · wf-form4_152114556039329.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · VP, Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,812 F1 · shares: Shares subject to this Form 4 were granted as part of a performance restricted stock unit granted May 31, 2017. All shares granted have been forfeited due to the single performance milestone being deemed not achievable by the Company. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 17:55 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Shares | 4,632 | $4.05 | $18,759.60 |
DisclosureSEC source: 0001013606-18-000012 · wf-form4_151821693730639.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,812 F2 · shares: Shares sold on February 7, 2018 to satisfy statutory minimum tax withholding obligations related to shares vested on February 4, 2018. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 17:55 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 33,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-18-000012 · wf-form4_151821693730639.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,444 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on February 17, 2016. 33% of the shares subject to this restricted stock award vested pursuant the terms of this award. Read SEC document |
| January 30, 2018 Filed Feb 22, 2018 14:45 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-012262 · doc4.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on January 30, 2018. The RSUs vest on the one year anniversary of the date of grant, so long as there has been no break in the Reporting Person's continuous service through such date. F3 · derivative.expiration_date: Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on January 30, 2018. The RSUs vest on the one year anniversary of the date of grant, so long as there has been no break in the Reporting Person's continuous service through such date. Read SEC document |
| January 30, 2018 Filed Feb 22, 2018 14:45 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001209191-18-012262 · doc4.xml · derivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2021-01-29 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will be fully vested and exercisable on January 30, 2021. Read SEC document |
| November 08, 2017 Filed Nov 8, 2017 16:12 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000168 · wf-form4_151017555336951.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,444 F1 · shares: Fifty percent of the restricted stock units shall vest eighteen months after date of grant, and the remaining balance will vest 36 months after the date of grant, in each case subject to continued service on the applicable vesting date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:34 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 110,000 | $4.82 Strike: $4.82 | $530,200.00 |
DisclosureSEC source: 0001013606-17-000097 · wf-form4_149643566933301.xml · derivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Option to Purchase · 110,000 shares Expires 2027-05-31 F2 · shares: Options vest ratably over forty-eight months. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:34 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000097 · wf-form4_149643566933301.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,186 F1 · shares: Performance restricted stock unit award based on a sales milestone. Read SEC document |
| April 06, 2017 Filed Apr 7, 2017 13:15 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Shares | 5,184 | $6.75 | $34,992.00 |
DisclosureSEC source: 0001013606-17-000039 · wf-form4_149158528745009.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,186 F2 · shares: Shares sold on April 6, 2017 to satisfy statutory minimum tax withholding obligations related to shares vested on April 4, 2017. Read SEC document |
| April 06, 2017 Filed Apr 7, 2017 13:15 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 55,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000039 · wf-form4_149158528745009.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,370 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on October 16, 2015. 25% percent of the shares subject to this restricted stock award vested pursuant the terms of this award. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 13:55 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Shares | 5,222 | $6.41 | $33,473.02 |
DisclosureSEC source: 0001013606-17-000028 · wf-form4_148830813030304.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,370 F2 · shares: Shares sold on February 27, 2017 to satisfy statutory minimum tax withholding obligations related to shares vested on February 22, 2017. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 13:55 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 55,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000028 · wf-form4_148830813030304.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,592 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on October 16, 2015. 25% percent of the shares subject to this restricted stock award vested pursuant the terms of this award. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 15:13 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Shares | 4,919 | $6.94 | $34,137.86 |
DisclosureSEC source: 0001013606-17-000016 · wf-form4_148667118099033.xml · nonDerivative · entry 2 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,592 F2 · shares: Shares sold on February 7, 2017 to satisfy statutory minimum tax withholding obligations related to shares vested on February 4, 2017. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 15:13 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 33,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000016 · wf-form4_148667118099033.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,511 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on February 17, 2016. 33% percent of the shares subject to this restricted stock award vested pursuant the terms of this award. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 16:52 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Shares | 20,000 | $6.25 | $125,000.00 |
DisclosureSEC source: 0001013606-16-000333 · wf-form4_148183876343555.xml · nonDerivative · entry 1 Mahboob Vaseem · CIK 0001655157 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,511 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.